-
Je něco špatně v tomto záznamu ?
Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013-2022
M. Liptáková, M. Malý, H. Orlíková, M. Špačková, R. Limberková, J. Kynčl
Status neindexováno Jazyk angličtina Země Polsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2014
Europe PubMed Central
od 2014
ProQuest Central
od 2010-01-01
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-07-29
Open Access Digital Library
od 2014-01-01
Nursing & Allied Health Database (ProQuest)
od 2010-01-01
Health & Medicine (ProQuest)
od 2010-01-01
Health Management Database (ProQuest)
od 2010-01-01
Public Health Database (ProQuest)
od 2010-01-01
Sciendo
od 2010-07-29
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
39319020
DOI
10.2478/sjph-2024-0027
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. METHODS: The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. RESULTS: A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0-89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35-44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. CONCLUSIONS: Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017712
- 003
- CZ-PrNML
- 005
- 20241016081853.0
- 007
- ta
- 008
- 241008s2024 pl f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2478/sjph-2024-0027 $2 doi
- 035 __
- $a (PubMed)39319020
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Liptáková, Monika $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0009000588204239
- 245 10
- $a Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013-2022 / $c M. Liptáková, M. Malý, H. Orlíková, M. Špačková, R. Limberková, J. Kynčl
- 520 9_
- $a INTRODUCTION: Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. METHODS: The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. RESULTS: A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0-89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35-44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. CONCLUSIONS: Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Malý, Marek $u National Institute of Public Health, Department of Biostatistics, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0009000164294023
- 700 1_
- $a Orlíková, Hana $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $u Charles University, Third Faculty of Medicine, Department of Epidemiology and Biostatistics, Ruská 87, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0000000202463645
- 700 1_
- $a Špačková, Michaela $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $u University of Defense, Military Faculty of Medicine, Třebešská 1575, 500 01 Hradec Králové, Czech Republic $1 https://orcid.org/0000000245571910 $7 xx0232062
- 700 1_
- $a Limberková, Radomíra $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic
- 700 1_
- $a Kynčl, Jan $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $u Charles University, Third Faculty of Medicine, Department of Epidemiology and Biostatistics, Ruská 87, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0000000208042729
- 773 0_
- $w MED00190087 $t Zdravstveno varstvo $x 0351-0026 $g Roč. 63, č. 4 (2024), s. 205-213
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39319020 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016081849 $b ABA008
- 999 __
- $a ok $b bmc $g 2196352 $s 1229663
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 63 $c 4 $d 205-213 $e 20240923 $i 0351-0026 $m Zdravstveno varstvo $n Zdr Varst $x MED00190087
- LZP __
- $a Pubmed-20241008